Apogee Therapeutics’ Post

This May, let's raise awareness by understanding its symptoms and diagnosis while recognizing the importance of finding new treatment options through clinical trials for Celiac Disease. Join Biopharma Informatic in advancing research for #CeliacDisease! Together, we can make a difference. #CeliacDisease #GlutenFreeLife #NoGluten #Clinicaltrials #ResearchStudies #HealthcareResearch

Safety and efficacy of #COROPROTECT kit as an add‑on therapy in the management of mild‑to‑moderate COVID‑19: A randomized, placebo‑controlled Clinical trial https://lnkd.in/dTYmRvEW Conclusion- #COROPROTECT kit as an adjuvant to conventional care is safe and offers faster clinical recovery, viral clearance, and symptom relief along with reduction in inflammatory markers and restoration in the immune cell levels in patients with mild-to-moderate COVID-19. Therefore, it can be considered as a safe and effective add-on regimen in the management of mild-to-moderate COVID-19.

𝗔𝘁 𝗮𝗻𝘆 𝗴𝗶𝘃𝗲𝗻 𝘁𝗶𝗺𝗲, 𝟰% 𝗼𝗳 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗴𝗿𝗮𝗽𝗽𝗹𝗲𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. Yet, of the estimated 10,000 rare diseases that have been identified, a staggering 95% lack FDA-approved treatments, leaving a vast majority searching for cures. These numbers underscore the intricate web of challenges in drug development for rare diseases—from diagnosis hurdles to regulatory pathways and the quest for sustainable treatments. Today, at the 19th Annual HD Therapeutics Conference, hosted by the CHDI Foundation, Alessandro Piai highlighted IRBM’s integrated approach and how we leverage our experience to drive even more progress toward the discovery of new therapeutics for rare diseases. 🧬 On this @Rare Disease Day, let's all recognize those who are affected by rare diseases and recommit to transforming the landscape of drug development, treatment, and care. Michele Luche Sara Tomaselli Carlo Toniatti Manuel Daldin Cristina Cariulo #rarediseaseday #huntingtonsdisease #irbm #hopeforacure

✨Editor’s Choice Articles Welcome to this paper on patients with cystic fibrosis and advanced lung disease, by Vincenzo Carnovale et al. from the University of Naples Federico II. 👉 Read the full article: https://lnkd.in/dMEtx7-B #clinical #medicine #openaccess #editorschoice #cysticfibrosis

While each rare disease is unique, rare disease patients often have one thing in common: an extensive timeline before reaching a diagnosis. Amplity Insights' blog discusses how pharma and biotech companies are catching patients earlier in their treatment journey: https://bit.ly/3XCPHo7

Why are #ClinicalStudies about CMS so important? 💭    Unfortunately, as of now there are not many large studies or established research about the experiences of those who have been diagnosed with CMS—particularly people who may not have received a confirmed diagnosis or underwent their specific mutation as adults.    As is the case with myasthenia gravis, neuromyelitis optica spectrum disease, or MOGAD antibody disease, more about CMS can be discovered via research studies, and particularly observational studies.     These studies can provide more insight on the initial characteristics of the disease as well as its progression, and as a result new therapies can be developed. It is up to us to participate in studies that can shed light on the experiences of those living with rare disease, so that additional studies can be designed that reflect the reality of the human experience.    To get more information on clinical studies in CMS and find out how we can help send us a DM or visit https://lnkd.in/eTF8zvam    -    #CongenitalMyasthenicSyndromes #CMS #eyedisease #raredisease #rarediseases #rarediseaseawareness #medicalresearch #clinicaltrials #clinicaltrial #KnowRare

While antinuclear antibody (ANA) testing serves as a crucial diagnostic tool for autoimmune rheumatic diseases, the interpretation and reporting of ANA test results face significant challenges due to the absence of standardized practices among laboratories. On June 6th, join the EUROIMMUN Academy and keynote speaker Dr. Carlos von Mühlen for a webinar on how to report ANA test results. Registration is now open! Click here to register. http://ms.spr.ly/6043Ykn17 #ANA #antinuclearantibodies #ICAP #reporting #guidelines #diagnostics

Further optimization and validation are required before potential broad use of ADC values to detect response to biologic therapy in patients with Crohn disease. https://lnkd.in/ezG8V64A

We are excited to share insights from our recent poster "Nebulized aerosol inhalation of LPS and dexamethasone is superior to intranasal delivery in the mouse model of lung neutrophilia”, which won the best poster award at the Models of Lung Disease 2024 conference. This fantastic work of our #SelvitaExperts addresses the challenge in treating lung diseases by comparing the efficacy of two drug delivery methodologies. If you want to learn the details and the conclusions, download the study here: https://bit.ly/4cGnIKH Stay updated on more research from Selvita by visiting our website: https://bit.ly/3xoKZiv #OurScience #poster #PulmonaryDiseases #LPS #LungNeutrophilia #nebulizedaerosol #dexamethasone #invivo #animalmodels

Our TestLine colleagues presented their work at the International Symposium on Tick-Borne Pathogens and Disease (ITPD) 2023. TestLine Clinical Diagnostics s.r.o., a member of BioVendor Group was there not only as one of the participants but also as one of the sponsors. They presented our key CLIA and Microblot-Array projects to the conference visitors. Lenka Pokorná together with Jana Dočkalová and Iva Stoklásková were co-authors of the poster by RNDr. Katerina Kybicova, PhD., which was devoted to the results of the comparison of the CLIA and EIA methods with the MicroBlot-Array method. In the clear graphs prepared by Lenka Pokorná, the level of antibody response to individual Borrelia antigens was compared not only in three groups of patients (with erythema migrans, neuroborreliosis and late Lyme disease), but also in a control group of healthy people. Congratulations TestLine, you’ve done a great job! #BioVendorGroup #diagnostics #tickborne #borreliosis #encephalitis #lymedisease